BPMC News and Press, Blueprint Medicines Corporation From 08/17/22

Gainers: Blue Water Vaccines ( BWV ) +57% . Eargo ( EAR ) +49% . Cassava Sciences ( SAVA ) +29% . MiNK Therapeutics ( INKT ) +24% . Cogent Biosciences ( COGT ) +16% . Losers: Blueprint Medicines ( BPMC ) -22% ....

Blueprint Medicines ( BPMC ) -13% on reports to seek label expansion for systemic mastocytosis therapy after trial win . Artelo Biosciences ( ARTL ) -13% . Krispy Kreme ( DNUT ) -12% on Q2 earnings release . Forza X1 ( FRZA ) -12% . ...

Blueprint Medicines ( NASDAQ: BPMC ), the maker of systemic mastocytosis therapy Ayvakit, said Tuesday that it would file a supplemental new drug application to the FDA this year after the treatment reached main goals in a registration trial for patients with the non-advanced ...

Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints PR Newswire -- AYVAKIT showed a superior mean change in total...

Pharmaceutical/biotechnology is the subsector with the highest value and quality scores. Life science tools and healthcare equipment are the most overvalued. Fast facts on IDNA. 10 stocks cheaper than their peers in August. This monthly article series shows a dashboa...

Blueprint Medicines Corporation (BPMC) Q2 2022 Earnings Conference Call August 2, 2022 8:00 A.M. ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer ...

Shares of oncology-focused Blueprint Medicines ( NASDAQ: BPMC ) surged ~13% in the morning hours Tuesday despite lower-than-expected financials for 2Q 2022 as management outlined plans to report data from a registration enabling trial for leading drug AYVAKIT in August. ...

Blueprint Medicines press release ( NASDAQ: BPMC ): Q2 GAAP EPS of -$2.68 misses by $0.45 . Revenue of $36.5M (+33.7% Y/Y) misses by $1.11M . As of June 30, 2022, cash, cash equivalents and investments were $947.2M, as compared to $1,034.6M ...

Blueprint Medicines Reports Second Quarter 2022 Results PR Newswire -- Achieved $36.5 million in total revenues, including $28.5 million in AYVAKIT® (avapritinib) net product revenues representing 20 percent AYVAKIT revenue growth from Q1 2022 -- -- ...

Blueprint Medicines  ( NASDAQ: BPMC ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is -$2.26 (-21.5% Y/Y) and the consensus Revenue Estimate is $37.61M (+37.8% Y/Y). Over the last 1 year, BPMC ...